The spinal muscular atrophy treatment ‘Spinraza’ has finally entered the last stage of its reimbursement extension in Korea.

According to Dailypharm coverage, Biogen is undergoing drug pricing negotiations with the National Health Insurance Service for its SMA treatment Spinraza (nusinersen).

Also, another SMA treatment, Roche Korea’s ‘Eveysdi (risdiplam)’ has passed the NHIS’s Drug Reimbursement Evaluation Committee review and has started pricing negotiations almost at the same time with Spinraza.

Discussions on the reimbursement and reimbursement extension of SMA treatments had seemingly made rapid progress due to rising demand for the abolition of Spinraza’s disc